Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-09-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-06-0367PMID 17000694
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.

  2006cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Contemporary management of thyroid cancer.

  2005cited by this paper
• Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

  2005cited by this paper
• Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.

  2005cited by this paper
• Perturbations of the AKT signaling pathway in human cancer

  2005cited by this paper
• Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

  2005cited by this paper
• Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer

  2005cited by this paper
• How Does Dna Methylation Mark the Fate of Cells?

  2004cited by this paper
• Histone Deacetylase Inhibitors Have a Profound Antigrowth Activity in Endometrial Cancer Cells

  2004cited by this paper
• Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis

  2004cited by this paper
• Histone-Deacetylase Inhibitors for the Treatment of Cancer

  2004cited by this paper
• Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.

  2003cited by this paper
• Histone acetylation and histone deacetylation

  2002cited by this paper
• Histone deacetylase inhibitors as new cancer drugs

  2001cited by this paper
• Inhibitors of histone deacetylase as new anticancer agents.

  2001cited by this paper
• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

  2000cited by this paper
• Anaplastic thyroid carcinoma: current diagnosis and treatment.

  2000cited by this paper
• DNA methylation: past, present and future directions.

  2000cited by this paper
• Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

  1998cited by this paper
• Roles of histone acetyltransferases and deacetylases in gene regulation

  1998cited by this paper
• Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines.

  1996cited by this paper
• Vitamin D compounds. Effect on clonal proliferation and differentiation of human myeloid cells.

  1986cited by this paper
• Synergistic interaction of anticancer agents: a cellular perspective.

  1975cited by this paper

• Epigenetic modifications in follicular cell-derived thyroid cancer: new dimensions in pathogenesis and treatment

  2025cites this paper
• Profilin-2 promotes tumour aggressiveness in oral squamous cell carcinoma via HDAC1 modulation: implications for EMT and targeted therapy

  2025cites this paper
• Epigenetic Targets and Their Inhibitors in Thyroid Cancer Treatment

  2023cites this paper
• Sodium/iodide symporter analysis for prognostication and management in thyroglobulin-elevated negative iodine scintigraphy syndrome: Current advances and future prospects

  2023cites this paper
• Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.

  2020cites this paper
• Enzymatic Synthesis of Ricinoleyl Hydroxamic Acid Based on Commercial Castor Oil, Cytotoxicity Properties and Application as a New Anticancer Agent

  2020cites this paper
• Fisetin Inhibits Cell Proliferation and Induces Apoptosis via JAK/STAT3 Signaling Pathways in Human Thyroid TPC 1 Cancer Cells

  2020cites this paper
• Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway

  2020cites this paper
• Histone Deacetylase Inhibitors and Papillary Thyroid Cancer.

  2020cites this paper
• Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells

  2019cites this paper
• Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma

  2019cites this paper
• Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance.

  2018cites this paper
• Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells.

  2018cites this paper
• AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair

  2018cites this paper
• Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells

  2018cites this paper
• Local and Systemic Treatment of Unresectable Disease

  2017cites this paper
• Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer.

  2017cites this paper
• Shikonin inhibits gefitinib‐resistant non‐small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway

  2017cites this paper
• Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.

  2016cites this paper
• The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells

  2016cites this paper
• SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.

  2016cites this paper
• Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

  2016cites this paper
• Combinatorial Study of a Novel Poly (ADP-ribose) Polymerase Inhibitor and an HDAC Inhibitor, SAHA, in Leukemic Cell Lines

  2016cites this paper
• Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells

  2016cites this paper
• Molecular Targeted Therapies of Aggressive Thyroid Cancer

  2015cites this paper
• Natural HDAC Inhibitors : Nature ’ s Answer to the Cancer

  2015cites this paper
• Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.

  2015cites this paper
• Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

  2015cites this paper
• The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo

  2015cites this paper
• Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap

  2015cites this paper
• Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation

  2015cites this paper
• New Therapies for Dedifferentiated Papillary Thyroid Cancer

  2015cites this paper
• Epigenetic inhibitors.

  2015cites this paper
• Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line

  2015cites this paper
• PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.

  2015cites this paper
• Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT

  2014cites this paper
• Advanced Thyroid Cancer Patients in Phase I Clinical Trials: Outcome Assessment and Literature Review

  2014cites this paper
• Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid

  2014cites this paper
• Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.

  2014cites this paper
• IMPORTANCE OF EPIGENETIC CHANGES IN THE THYROID CANCER INCIDENCE AND THEIR THERAPEUTIC APPLICATIONS (REVIEW ARTICLE)

  2014cites this paper
• Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro

  2014cites this paper
• Importance of Epigenetic Changes in the Thyroid Cancer Incidence and Their Therapeutic Applications

  2014cites this paper
• Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma

  2013cites this paper
• Vitamin D in thyroid tumorigenesis and development.

  2013cites this paper
• New developments in the diagnosis and treatment of thyroid cancer

  2013cites this paper
• Intravesical Treatment with Vorinostat Can Prevent Tumor Progression in MNU Induced Bladder Cancer

  2013cites this paper
• Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

  2013cites this paper
• Key genes and pathways in thyroid cancer based on gene set enrichment analysis.

  2013cites this paper
• Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells

  2013cites this paper
• Valproic Acid Sensitizes TRAIL-Resistant Anaplastic Thyroid Carcinoma Cells to Apoptotic Cell Death

  2013cites this paper
• Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment

  2013cites this paper
• Targeting histone deacetylase in thyroid cancer

  2013cites this paper
• A Proposal Regarding Reporting of In Vitro Testing Results

  2013cites this paper
• Determination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study.

  2013cites this paper
• Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo.

  2013cites this paper
• RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

  2013cites this paper
• Redifferentiation Therapy in Thyroid Cancer

  2012cites this paper
• SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin

  2012cites this paper
• Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.

  2012cites this paper
• Novel molecular targeted therapies for refractory thyroid cancer

  2012cites this paper
• CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells.

  2012cites this paper
• Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer

  2012cites this paper
• Targeted Therapy of Thyroid Cancer

  2012cites this paper
• Phase II Trial of Vorinostat plus Tacrolimus & Mycophenolate to prevent Graft versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant Blood and Marrow Transplantation Program University of Michigan Comprehensive Cancer Center

  2012cites this paper
• Hydroxamic acids (therapeutics and mechanism): chemistry, acyl nitroso, nitroxyl, reactive oxygen species, and cell signaling

  2011cites this paper
• The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells

  2011cites this paper
• The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome.

  2011cites this paper
• Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

  2011cites this paper
• Protein arginine deiminase 4: a target for an epigenetic cancer therapy

  2011cites this paper
• Epigenetics of thyroid cancer and novel therapeutic targets.

  2011cites this paper
• Sodium butyrate induces cell senescence in transformed rodent cells resistant to apoptosis

  2011cites this paper
• Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.

  2011cites this paper
• The Role of Epigenetic Modifications in Cancer

  2011cites this paper
• ÈÍÄÓÊÖÈß ÊËÅÒÎ×ÍÎÃÎ ÑÒÀÐÅÍÈß ÈÍÃÈÁÈÒÎÐÎÌ

  2011cites this paper
• The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy

  2011cites this paper
• 1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.

  2011cites this paper
• Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

  2010cites this paper
• Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells

  2010influential citation
• Carcinogenesis and therapeutic strategies in thyroid cancer.

  2010cites this paper
• Vorinostat increases carboplatin and paclitaxel activity in non‐small cell lung cancer cells

  2010cites this paper
• Emerging molecular therapies of advanced thyroid cancer.

  2010cites this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer

  2010cites this paper
• RESEARCH PAPER Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

  2010cites this paper
• [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].

  2009cites this paper
• Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

  2009cites this paper
• Effect of histone deacetylase inhibitor sodium butyrate (NaB) on transformants E1a+cHa-Ras expressing wild type p53 with suppressed transactivation function

  2009cites this paper
• Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.

  2009cites this paper
• Antitumour activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo

  2009cites this paper
• Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes

  2009cites this paper
• Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.

  2009cites this paper
• Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.

  2009cites this paper
• KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling

  2008cites this paper
• Dedifferentiated thyroid cancer: a therapeutic challenge.

  2008cites this paper
• PHARMACOTHERAPY IN ADVANCED THYROID CANCER

  2008cites this paper
• Induction of sodium iodide symporter gene and molecular characterisation of HNF3β/FoxA2, TTF-1 and C/EBPβ in thyroid carcinoma cells

  2008cites this paper
• Histone deacetylase inhibitors in lymphoma and solid malignancies

  2008cites this paper
• Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo.

  2008cites this paper
• Cancer stem cells and individualized therapy.

  2007cites this paper
• Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases

  2007cites this paper
• New perspectives on the treatment of differentiated thyroid cancer.

  2007cites this paper